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Background: XinJiErKang (XJEK), a Chinese herbal formula, is identified as an effective preparation to treat coronary
heart disease and myocarditis. The aim of the study is to investigate the anti-hypertensive effects of XJEK by oral
administration and also to find out whether the drug has any role in oxidative stress and vascular endothelial function.
Methods: Clipping of the renal artery resulted in gradual elevation of the systolic blood pressure (SBP) which reached
a plateau after 4 weeks of surgery. Treatment of hypertensive rats (20 mmHg higher than basic systolic blood pressure)
with XJEK (6, 12, 24 g/kg/day) and fosinopril (15 mg/kg/day) respectively by intragastric administration started 4 weeks
after surgery and continued for 4 weeks. The sham-operated (Sh-Op) controls received drinking water. BP was
monitored weekly using tail-cuff apparatus. At the end of 8 wk, left ventricular systolic pressure (LVSP), left ventricular
end-diastolic pressure (LVEDP), rate of rise of left ventricular pressure (±dp/dtmax) were examined (PowerLab 8/30,
AD Instruments, Australia). The myocardial hypertrophy index was expressed as heart weight/body weight (HW/BW),
the histological changes were investigated by hematoxylin and eosin (HE) and Van Gieson (VG) stain.
Endothelium-dependent relaxations due to acetylcholine were observed in isolated rat thoracic aortic ring
preparation. Superoxide dismutase (SOD) activity, malondialdehyde (MDA) and nitric oxide (NO) content in serum,
contents of hydroxyproline (Hyp) in the ventricular tissue were assayed by xanthin oxidase method, thiobarbituric
acid (TBA) method, Griess method and alkaline hydrolysis method, respectively. Angiotensin II (Ang II) content in
serum was detected by radioimmunoasssay method.
Results: XJEK therapy potently improved cardiac function, inhibited myocardial hypertrophy, improved cardiac
pathology change, decreased the myocardial cross-section area (CSA), collagen volume fraction (CVF) and
perivascular circumferential collagen area (PVCA), reduced the content of Hyp in the left ventricular tissue,
inhibited the decrease of SOD activity and increase of MDA, Ang II content in serum. Moreover, treatment with
XJEK improved endothelial dysfunction (ED) manifested by promoting endothelial-dependent vasodilation of
thoracic aortic rings and enhancing the NO activity in serum.
Conclusions: These findings suggest that administration of XJEK possess protective effects against 2K1C induced
hypertension and cardiac remodeling in rats, preserve NO activity and endothelial function.
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Human hypertension is usually a slowly-developing dis-
order from middle to old age. Hypertension is not only
manifested by an increased arterial pressure, it also in-
volves the complex structural and functional alterations
of its target organs. Long-term hypertension often re-
sults in left ventricular hypertrophy, which is considered
to be a risk factor for coronary heart disease, congestive
heart failure (CHF), ventricular arrhythmia, and sudden
death [1], as well as structural alteration of the vascular
wall, which is manifested by endothelial dysfunction (ED),
extracellular matrix deposition and medial layer thicken-
ing because of hypertrophy/hyperplasia and migration of
vascular smooth muscle cells (VSMCs). Epidemiological
data revealed that hypertension is responsible for 54% of
stroke, 47% of ischemic heart disease, and 25% of other
cardiovascular diseases worldwide; a total of 6.7 million
deaths throughout the world (≈13.5% of all) are ascribed
to high blood pressure [2]. On the other hand, chronic
kidney artery diseases, such as renal artery stenosis, gener-
ally lead to hypertension, and one of the kidney related
animal models of hypertension is 2-kidney, 1-clip (2K1C)
model in which one of the renal arteries is subjected to
partial stenosis by clip placement. Kidney ischemia re-
sults in increase in plasma renin and angiotensin activity
[3] which in turn leads to persistent increase in blood
pressure. In experimental renovascular hypertension,
increased oxidative stress (OS) plays an important part
in the pathogenesis of renovascular hypertension and
the enhancement of the oxidation-sensitive signaling
pathway [4]. Previous studies have reported that angio-
tensin II (Ang II) stimulates the production of reactive
oxygen species (ROS) such as superoxide through the
activation of membrane-bound NADH or NADPH oxi-
dase [5,6]. Recently, ED is known to play important
roles in the pathogenesis and progressiveness of hyper-
tensive heart disease [7]. One of the key factors in ED is
the overproduction of ROS which participates in the de-
velopment of hypertension, atherosclerosis, diabetes,
cardiac hypertrophy, heart failure, ischemia-reperfusion
injury, and stroke [8].
Xin-Ji-Er-Kang (XJEK) is a topical Chinese herbal medi-
cine (CHM) compound made from fourteen herbal medi-
cines such as Panax ginseng, Astragalus mongholicus Bunge,
Ophiopogon japonicus, Polygonatum odoratum and so
on. Both clinical study and basic research have exhibited
the curative effect of XJEK on hypertension induced cor-
onary heart disease, virus myocarditis and toxic myocardi-
tis [9,10]. XJEK has also been shown to exert protective
effects against isoproterenol-induced ventricular remodel-
ing in mice, which may be related to its actions in redu-
cing the oxidative stress and improving the antioxidant
activity of the body [11]. Our preliminary experiment re-
sults also demonstrated that XJEK prevented heart, kidney,vascular remodeling and injury in 2K1C induced hyperten-
sion rats [12].
The aims of this research, therefore, are to reveal whether
XJEK can prevent 2K1C-induced hypertension and car-
diovascular remodeling (CR) and, if so, to determine the
underlying mechanism, focusing on the involvement of
OS and ED.
Methods
Preparation of XJEK extract
XJEK consists of fourteen medicinal compositions as shown
in Table 1. All of these herbs were purchased from Hefei
Company of Traditional Crude Drugs (Hefei, China), and
carefully authenticated by Dr. He-ping Huang (AnHui
College of Traditional Chinese Medicine, HeFei, China).
Voucher specimens (numbers were listed in Table 1)
were deposited at the Herbarium of Nanjing University
of Traditional Chinese Medicine (Nanjing, China). After
drying, these plant materials were mixed in proportion
and were macerated for 1 h at room temperature with
eight times (v/w) distilled water. Then the whole mixture
was decocted twice for 1 h each time. The filtrates were
mixed and condensed and then dried by vacuum-drier at
60°C. The yield of XJEK extract was 25.6% (w/w) according
to the original herbs. The resulting powder, stored at −20°C,
was diluted to the concentrations needed with distilled water
and filtered before use.
Animals and treatment
Fifty-four male Wistar rats (200 ± 10 g) were purchased
from the Laboratory Animal Center of Nanjing Medical
University. All procedures were performed in accordance
with the protocol outlined in the Guide for the Care and
Use of Laboratory Animals published by the US National
Institute of Health (NIH publication no. 85–23, revised
1996) and approved by the Committee on the Ethics of
Animal Experiments of An’hui Medical University. The
animals were housed under standardized conditions, 12 h
dark–light cycle in solid bottomed polypropylene cages,
and received commercial rat chow ad libitum.
2K1C hypertension was induced by subjecting the
animals to right renal artery clamping using a 0.25 mm
silver clip under pentobarbital anesthesia. The animals
were randomly assigned to one of six groups. 1: Sham-
operated (Sh-Op) rats underwent the same surgical pro-
cedure, except for the placement of the renal artery clip. 2:
Experimentally induced hypertensive model group that
underwent right renal artery clamping (2K1C) and re-
ceived tap water; 3: XJEK low dose group: Rats under-
went 2K1C and received XJEK at 6 g/kg/day; 4: XJEK
middle dose group: Rats underwent 2K1C and received
XJEK at 12 g/kg/day; 5: XJEK high dose group: Rats under-
went 2K1C and received XJEK at 24 g/kg/day; 6: Fosinopril
group: Rats underwent 2K1C and received fosinopril at
Table 1 Recipe of XJEK formulation
Components Voucher specimens number Part used Rate (%)
Panax ginseng C.A. Mey. NJUTCM-20110530 Root 11.71
Polygonatum odoratum (Mill.) Druce NJUTCM-20110531 Rhizome 7.03
Panax pseudoginseng var. notoginseng (Burkill) G. Hoo & C.L. Tseng NJUTCM-20110532 Root 3.09
Allium macrostemon Bunge NJUTCM-20110533 Ramulus 7.80
Angelica sinensis (Oliv.) Diels NJUTCM-20110534 Root 7.80
Ophiopogon japonicus (Thunb.) Ker Gawl. NJUTCM-20110535 Root 7.80
Schisandra chinensis (Turcz.) Baill. NJUTCM-20110536 Fruit 3.93
Salvia miltiorrhiza f. alba C.Y. Wu & H.W. Li NJUTCM-20110537 Root 7.80
Sophora flavescens Aiton NJUTCM-20110538 Root 7.80
Glycyrrhiza acanthocarpa (Lindl.) J.M. Black NJUTCM-20110539 Rhizome 7.80
Astragalus mongholicus Bunge NJUTCM-20110540 Root 11.69
Epimedium acuminatum Franch. NJUTCM-20110541 Aerial part 7.80
Trichosanthes obtusiloba C.Y. Wu NJUTCM-20110542 Seed 7.80
Dryobalanops aromatica C.F. Gaertn. NJUTCM-20110543 Resin 0.15
Yu et al. BMC Complementary and Alternative Medicine 2013, 13:173 Page 3 of 10
http://www.biomedcentral.com/1472-6882/13/17315 mg/kg/day. Treatment with XJEK was started 4 weeks
after 2K1C hypertension was induced and maintained for
an additional 4 weeks. Body-weight (BW) and tail systolic
blood pressure (SBP) were assessed weekly throughout the
experimental period.
Measurement of systolic blood pressure
SBP was measured in all groups using the tail-cuff ap-
paratus (ALC-NIBP, Shanghai Alcott Biotech CO., LTD.)
at weekly intervals. Before the measurements, the rats were
warmed for 30 min at 28°C in order to allow the detection
of tail artery pulsations and to achieve a steady pulse level.
SBP was obtained by averaging 10 measurements.
Haemodynamics and cardiac remodeling index
At the end of eight weeks, all animals were anaesthetized
with pentobarbital (45 mg/kg, intraperitoneal injection),
the right carotid artery was cannulated with a polyethylene
catheter connected to a Statham transducer and then the
catheter was inserted along the right coronary artery
into the left ventricle, and the signals were recorded on
a PowerLab 8/30 (AD Instruments, Australia) and digit-
ally sampled (1 kHz) on a personal computer using a
chart software (version 5.3). The left ventricular systolic
pressure (LVSP), left ventricular end-diastolic pressure
(LVEDP) and rate of rise of left ventricular pressure
(±dp/dtmax) were recorded.
Thereafter, blood samples were collected and centrifuged
for 10 min at 3000 rpm, and all samples were stored at −80°C
for further use. Then the animals were killed by exsan-
guinations, and the thoracic cavity was opened to ex-
pose the still beating heart. The hearts were rapidly
removed, rinsed in ice-cold 0.9% NaCl solution, blotted
and weighed. The heart–weight index (HW/BW) wascalculated by dividing the heart weight by the body
weight.
Measurement of plasma Ang II levels
Blood from the abdominal aorta was collected into a
chilled glass tube containing protease inhibitors and
Enalapril to inhibit ex vivo conversion of Ang I to Ang II
(Sigma, St. Louis, MO). After elution from the column
with 90% methanol, samples were dried and reconstituted
for radioimmunoassay (RIA). The RIA for Ang II was
performed using 125 I-angiotensin II (Perkin-Elmer, Foster
City, CA) and rabbit anti-Ang II antibody (Phoenix Phar-
maceuticals, Inc., Belmont, CA) with cross-reactivity of <2%
for Ang II precursors and degradation products. After in-
cubation for 48 h at 4°C, bound and free Ang II was sepa-
rated with dextran-coated charcoal. The supernatant was
counted with a gamma-counter (ICN, Costa Mesa, CA).
The ratio B/Bo was corrected for non-specific binding,
expressed as a percentage of maximal binding, and read
against a standard curve (log-logit transformation).
Histological and morphological analyses of the heart and
thoracic aorta
After weighing the heart, 70% of the upper hearts were
frozen in liquid nitrogen for measuring the contents of
hydroxyproline, and the other 30% were fixed in 10%
formalin for histological analysis. Briefly, paraffin sections
(5 μm) were cut and stained with hematoxylin and eosin
(HE) and Van Gieson (VG). Thereafter, the myocyte
cross-sectional area (CSA), perivscular collagen area (PVCA)
and collagen volume fraction (CVF) were quantitatively
analysed with NIH Image 1.61 software (National Insti-
tutes of Health Service Branch) in digitalized microscopic
images as has been previously described [13].
Figure 1 Development of SBP in the six experimental groups
during a 8-week period. Nine time points of SBP were measured
using tail-cuff apparatus measurement in each group. Data are
expressed as the mean ± SD, n = 8 ~11. *P < 0.05, **P <0.01 vs Sh-Op
group; #P < 0.05, ##P < 0.01 vs model group.
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before use, and then tissues were cleaned and fixed in
formaldehyde. Paraffin-embedded thoracic aorta (5 μm)
was cut, dewaxed and stained with HE. The structural
changes of aorta were investigated using a light micro-
scope. Area of total aorta (TAA), area of lumen (LA),
CSA, aorta radius (AR), luminal radius (L), and media
thickness (M) of aorta were recorded under a light micro-
scope, and the ratio of M/L was calculated as has been
previously reported [13].
Isolated vascular ring experiments
Isolated vascular ring experiments were performed as we
previously described [14], with minor modification. In
brief, four-millimeter ring segments of the descending
thoracic aorta were dissected and mounted in individual
organ chambers filled with Krebs buffer (composition
in mM): NaCl 118, KCl 4.75, NaHCO3 25, MgSO4 1.2,
CaCl2 2, KH2PO4 1.2, glucose 11. The solution was
continuously gassed with a 95% O2 and 5% CO2 mix-
ture and maintained at 37°C. Rings were stretched to
0.5 g of resting tension by means of two L-shaped stain-
less steel wires, which were inserted into the lumen and
attached to the chamber and to an isometric force-
displacement transducer. Rings were equilibrated for 60
to 90 min, during which, tissues were restretched and
washed every 30 min with warm Krebs solution. The
concentration-relaxation response curves to acetylcho-
line (10-8-10-4 mol/L) were performed in intact rings
precontracted by 10-4 mol/L phenylephrine. Relaxant
responses to acetylcholine were expressed as a percent-
age of precontract induced by phenylephrine.
Measurement of nitric oxide (NO), total superoxide
dismutase (SOD) activities, malondialdehyde (MDA)
content in serum and hydroxyproline (Hyp) content in
cardiac tissue
The methods of measuring NO have been described
previously [15]. Because of its instability in physiological
solutions, most of the NO was rapidly converted to
nitrite (NO2
- ) and further to nitrate (NO3
- ). Serum levels
of NO2
-/NO3
- were measured using NO Detection Kit
according to the manufacturer’s instruction. Briefly,
nitrate was converted to nitrite with aspergillus nitrite
reductase, and the total nitrite was measured with the
Griess reagent. The absorbance was determined at 540 nm
with a spectrophotometer.
As has been described previously [16], MDA content
was measured using thiobarbituric acid reactive substances
(TBARS) assay following the manufacturer’s instruction
(Jiancheng Institute of Bioengineering Company, Nanjing,
China) by measuring the absorbance value at wave-
length of 532 nm. SOD activity was measured using
xanthine oxidase method to measure the absorbancevalue at 550 nm with SOD kit (Jiancheng Bioengineer-
ing, Nanjing, China).
The contents of Hyp in cardiac muscle were measured
as described formerly [13] according to the explanations
provided by the manufacturer.
Statistical analysis
All data are expressed as mean ± SD. For all the statistical
tests, multiple comparisons were performed by one-way
ANOVA with Tukey–Kramer exact probability test. The
least-squares method was used for linear correlation
between selected variables. Statistical significance was
accepted at P < 0.05.
Results
Effect of XJEK on SBP
SBP was considerably lower in the XJEK and fosinopril
treated hypertensive rats as compared to experimentally
induced hypertensive model group. A progressive reduc-
tion in BP was observed in XJEK and fosinopril treated
groups from 5 week (P < 0.05, P < 0.01; Figure 1). At the
end of 8 weeks, experiment animals treated with XJEK
(each dose) and fosinopril demonstrated reduced SBP sig-
nificantly, which was near to the SBP of Sh-Op group rats.
Effect of XJEK on haemodynamic parameters
The measurements of in vivo left ventricular function for
all groups were measured 8 weeks after 2K1C. As shown
in Table 2, systolic cardiac parameters, including LVSP,
LVEDP, +dp/dtmax, and diastolic cardiac parameter -dp/
dtmax, were all significantly elevated in model group rats.
These changes could also be prevented by treatment with
Table 2 Effects of XJEK on cardiac function in 2K1C hypertensive rats (mean ± SD, n = 8 ~ 11)
Group LVSP(mmHg) LVEDP(mmHg) +dP/dtmax(mmHg/s) -dP/dtmax(mmHg/s)
Sh-Op 113.07 ±11.66 27.56 ±9.11 7672.57 ± 2158.28 −7046.04 ±1501.92
Model 149.21 ± 20.68** 46.93 ± 19.92** 8477.46 ± 1123.74 −7483.98 ±1122.43
XJEK
6 g/kg 121.34 ± 16.99## 40.88 ±7.40 7358.72 ± 1389.27 −7679.91 ±1906.72
12 g/kg 115.61 ± 14.16## 35.66 ±9.49 7140.11 ± 2493.83 −7666.94 ±1235.32
24 g/kg 113.60 ± 15.86## 37.93 ±4.28 6310.59 ± 1588.00## −7015.20 ± 1162 .04
Fosinopril
15 mg/kg 110.53 ± 11.26## 36.65 ±12.28 6514.32 ±2417.83# −7152.12 ±1789.97
LVSP left ventricular systolic pressure, LVEDP left ventricular end-diastolic pressure, +dp/dtmax maximal rate of left ventricular systolic pressure, -dp/dtmax maximal
rate of left ventricular diastolic pressure. **P < 0.01 vs Sh-Op group; #P < 0.05, ##P < 0.01 vs model group.
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observed in positive drug-fosinopril treated group.
Effect of XJEK on cardiac remodeling in 2K1C rats
Histology of the hearts from the experimentally induced
hypertensive model group rats showed that myocyte CSA,Figure 2 Effects of XJEK on HW/BW, myocyte CSA of cardiac tissue in 2
×400); (B) Representive figure of myocyte long axis (HE staining, ×400); (C) St
group; 2: model group; 3:2K1C + XJEK 6 g/kg group; 4:2K1C + XJEK12g/kg gro
The HW/BW ratios, myocyte CSA increased significantly compared with the Sh
pathological changes, as well as the positive control fosinopril. Data are e
##P < 0.01 vs model group.and levels of CVF, PVCA increased significantly (**P < 0.01)
as compared with those of the Sh-Op group (Figure 2-A,B,
D and Figure 3-A,B,C,D). Morphological hypertrophy
of heart was characterized by an increase in HW/BW
ratios, which boosted significantly (**P < 0.01) compared
with those of the Sh-Op group (Figure 2-C), whereas theK1C rats. (A) Representive figure of myocyte cross-section (HE staining,
atistic results of HW/BW; (D) Statistic results of myocyte CSA. 1: Sh-Op
up; 5: 2K1C + XJEK 24 g/kg group; 6:2K1C + fosinopril 15 mg/kg group.
-Op group. XJEK at all doses for 4 weeks could reverse these
xpressed as mean ± SD, n = 8 ~ 11. **P <0.01 vs Sh-Op group; #P < 0.05,
Figure 3 (See legend on next page.)
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Figure 3 Effects of XJEK on myocardial fibrosis, perivascular fibrosis, and cardiac Hyp content in 2K1C rats. (A) Representive figure of
myocardial fibrosis (VG staining, ×400); (B) Representive figure of perivascular fibrosis (VG staining, ×400); (C) Statistic results of myocardial fibrosis;
(D) Statistic results of perivascular fibrosis; (E) Statistic results of cardiac Hyp content in cardiac tissue. Group divided ibidem. Levels of myocardial
and perivascular fibrosis, and the cardiac Hyp content all increased significantly compared with the Sh-Op group. XJEK at all doses for 4 weeks
could reverse these pathological changes, as well as the positive control fosinopril. Data are expressed as mean ± SD, n = 8 ~ 11. *P < 0.05, **P <0.01 vs
Sh-Op group; #P < 0.05, ##P < 0.01 vs model group.
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(data not shown). Moreover, the hydroxyproline content –
reflecting the collagen level in cardiac tissue and the
extent of myocardial fibrosis increased by 17.86% in
experimentally induced hypertensive model group rats
as compared with that of the Sh-Op group (Figure 3-E).
XJEK at all doses for 4 weeks could reverse those patho-
logical changes, as well as positive drug-fosinopril.
Effect of XJEK on aortic remodeling in 2K1C rats
The vascular remodeling of the upper thoracic aorta ex-
posed to 2K1C rats was observed at the end of 4th week.
Compared with Sh-Op group rats, the values of the area
of the TAA, LA, CSA, AR, M, and M/L ratio of the aorta
in 2K1C rats were markedly increased. These changes
could be prevented by treatment with XJEK at all doses for
4 weeks, as well as the positive drug (Table 3, Figure 4).
Effect of XJEK on endothelial dysfunction in 2K1C rats
Aortic rings from unilateral renal clipping treated animals
showed strongly reduced endothelium-dependent vaso-
dilator responses to acetylcholine in arteries stimulated by
phenylephrine compared to those in the Sh-Op (Figure 5).
The aortic rings obtained from 2K1C rats treated with
both XJEK and fosinopril showed a significant increase in
vasodilatation induced by acetylcholine compared to the
rings from the model group.
Effect of XJEK on serum Ang II content
The concentrations of Ang II measured in serum after
8 weeks are shown in Figure 6. Ang II content in 2K1CTable 3 Effect of XJEKs on aorta remodeling in 2K1C rats (me
Group TAA (×103um2) LA (×103um2) CSA (×103um2) CSA/TAA
Sh-Op 2671.83 ± 108.18 2354.67 ± 99.27 317.17 ± 56.36 11.86 ± 1.9
Model 2819.57 ± 82.65** 2454.29 ± 71.59* 365.29 ± 86.36 12.92 ± 2.8
XJEK
6 g/kg 2854.00 ± 162.03 2505.29 ± 176.62 348.71 ± 35.81 12.27 ± 1.6
12 g/kg 2764.00 ± 185.83 2411.33 ± 250.26 352.67 ± 66.40 12.90 ± 3.1
24 g/kg 2694.33 ± 82.08## 2379.67 ± 65.31# 314.67 ± 45.65# 11.66 ± 1.5
Fosinopril
15 mg/kg 2692.13 ± 77.46## 2410.13 ± 111.76 282.00 ± 56.86## 10.50 ± 2.2
TAA area of total aorta, LA area of lumen, CSA cross-sectional area, AR aorta radius.
observed at the end of 4th week, which could be prevented by treatment with XJ
**P <0.01 vs Sh-Op group; #P < 0.05, ##P < 0.01 vs model group.treatment is obviously increased than that in the Sh-Op
group. Besides, administration of XJEK markedly reduced
Ang II concentration in a dose-dependent manner, as well
as the fosinopril group (P < 0.01, Figure 6-A).
Effect of XJEK on serum SOD activity, MDA content and
NO content in 2K1C rats
Lower SOD was found in 2K1C hypertensive rats com-
pared with Sh-Op, and XJEK treatment restored SOD
activity (Figure 6-B). Serum MDA was observably increased
in the 2K1C group in 4th wk compared with Sh-Op group.
Administration with XJEK at all doses for 4 weeks inhibited
the increase of serum MDA markedly (Figure 6-C). Serum
NO contents were significantly decreased in 2K1C group in
comparison with Sh-Op group and XJEK administration
at all doses for 4 weeks increased NO contents markedly
(Figure 6-D).
Discussion and conclusions
The main findings of the present study reveal that treat-
ment with XJEK prevents hypertension and cardiovascu-
lar remodeling in unilateral renal clipping rats, which
seems to be related to the attenuation of OS. Furthermore,
the results also indicate that XJEK moderate ED, con-
firmed by increasing serum NO production, which may
cooperate with their beneficial cardiovascular effects.
This is the first study to compare the effects of significantly
different doses of XJEK on biochemical, morphological and
functional alterations caused by 2K1C hypertension.
Renovascular hypertension in the 2K1C model is char-
acterised by elevated Ang II expression resulted froman ± SD, n = 8 ~ 11)
(%) AR (um) Lumen (um) Media (um) Media/lumen (%)
9 374.58 ± 16.07 339.72 ± 18.89 34.86 ± 4.85 10.33 ± 1.90
1 405.23 ± 13.43** 357.43 ± 12.14* 47.80 ± 5.27** 13.39 ± 1.52**
6 408.76 ± 20.55 364.43 ± 24.35 44.32 ± 4.79 12.27 ± 2.10
3 400.35 ± 26.12 354.46 ± 29.84 45.89 ± 4.95 13.06 ± 2.31
2 383.59 ± 11.80## 347.32 ± 16.20 36.27 ± 11.11## 10.54 ± 3.54#
8# 384.36 ± 26.74# 347.05 ± 33.86 37.30 ± 13.02# 11.11 ± 4.93
The vascular remodeling of the upper thoracic aorta exposed to 2K1C was
EK at all doses for 4 weeks, as well as the positive drug fosinopril. *P < 0.05,
Figure 4 Representative figure of aortic remodeling in different groups. (HE staining, ×40) Group divided ibidem.
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non-clipped kidney, sustained increase of blood pressure
and the following cardiovascular remodeling. CR is de-
fined as genome expression, especially the re-expression
of fetal isoforms such as atrial natriuretic peptide (ANP)
[17], cellular, including the enlargement of cell size and
mass of individual cardiomyocytes without an increase in
cell number; and interstitial fibrosis, manifested clinically
as changes in the size, shape, and function of the heart
after cardiac injury [18]. Various harmful sequelae of car-
diovascular diseases and conditions such as coronary heartFigure 5 XJEK and positive drug decrease contraction of the
thoracic aorta from 2K1C rats. Data are expressed as the mean ± SD,
n = 8 ~11. *P < 0.05 vs Sh-Op group; #P < 0.05, ##P < 0.01 vs
model group.disease, stroke, congestive heart failure and sudden death
are known to be aggravated by CR [19,20]. Apart from
CR, this experimental model is also associated with
changes in the structural and mechanical properties of
the arteries (named vascular remodeling, VR), including
arterial wall hypertrophy and an increase in media/lumen
ratio, changes in vascular wall stiffness ascribing to the
up-regulation of matrix metalloproteinases (MMPs) [21]
and severe renal histopathological lesions (such as
glomerular hypertrophy, tubulointerstitial damage and
glomerular volume) [22]. These changes increase vascular
resistance to flow, further compounding the elevation in
blood pressure. In accordance with these previous studies,
the present study reveals that 2K1C treatment results
in prominent cardiovascular remodeling, manifested as
elevation in HW/BW and CSA, and increase in collagen
deposition, wall thickness, TAA, media thickness. Our
present results also demonstrate that chronic oral ad-
ministration with XJEK prevents hypertension and cardio-
vascular remodeling in this 2K1C-induced hypertensive
rat model.
Ang II is the primary effector molecule of the renin–
angiotensin system. It is primarily recognized for its role
in the regulation of arterial pressure and blood volume
[23]. In addition to its pressor effect, Ang II has a variety
of non-hemodynamic actions. For example, Ang II–in-
duced cell growth and fibrosis may bring about left ven-
tricular hypertrophy and vascular remodeling. Recently,
the role of OS in cardiovascular diseases has been char-
acterized. Many of the deleterious cellular phenotypes
presented in hypertrophied and failing myocardium might
Figure 6 Effects of XJEK on serum Ang II concentrations (A), SOD content (B), MDA content (C) and NO content (D) in 2K1C rats. Group
divided ibidem. Data are expressed as mean ± SD, n = 8 ~ 11. *P < 0.05, **P <0.01 vs Sh-Op group; #P < 0.05, ##P < 0.01 vs model group.
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oxidase-derived ROS production plays a critical role in the
hypertension induced by Ang II. In a model of in vivo
cardiac hypertrophy induced by short-term (7–14 day)
sub-pressor infusion of Ang II [24], it has been found
that increase in heart/body weight ratio, myocyte area
and mRNA expression of ANF and β-MHC, whilst admin-
istration of a NADPH oxidase inhibitor reduces vascular
O2
.- production and attenuates Ang II-induced increase in
blood pressure [25]. This NADPH oxidase-derived ROS
function as secondary messengers activating myriad redox-
sensitive downstream targets, such as RAS, c-src, the
MAPKs, the PI3 kinase (PI3K)/Akt pathway, NF-κB,
AP-1, HIF-1 and others, the significant role of which
has been confirmed in cardiovascular remodeling [26].
Furthermore, these excessively generated ROS may
directly react with NO, thereby stimulating the pro-
duction of the NO/superoxide anion reaction product
peroxynitrite (ONOO-), accordingly, increased ONOO-
may impair the function of the endothelial NO synthase
(eNOS) by reducing the bioavailability of its co-enzymetetrahydrobiopterin (BH4), which is required for NOS
dimer formation and only if in this coupled state eNOS
consumes NADPH and generates NO and L-citrulline
from L-arginine and O2. The decreasing bioavailability
of BH4 induces an unstable structure of eNOS, a
phenomenon known as ‘eNOS uncoupling’ and on protein
gels, it appears more as a monomer, and electrons become
diverted to molecular oxygen rather than to L-arginine,
resulting in O2
- formation, which thereby causes an anti-
cardiovascular remodeling NO-producing enzyme to
become a ROS-producing one, and accelerates the car-
diovascular remodeling process hence [27]. Our
present study reveals that blunted endothelium-dependent
relaxation response to acetylcholine in noradrenaline pre-
contracted aortic rings and decrease NO content in serum,
accompanied with OS in this 2K1C rats hypertensive rat
model. Ginseng, Astragalus mongholicus, Radix Ophiopogo-
nis and Polygonatum odoratum are the main components of
XJEK formula. It has been reported that ginsenoside exists
in ginseng, and total flavonoids of Astragalus (the active
component of Astragalus mongholicus Bunge) and the
Yu et al. BMC Complementary and Alternative Medicine 2013, 13:173 Page 10 of 10
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dant activity [28-30]. Our present study demonstrates that
chronic treatment with XJEK prevents ED and OS in a
doses-dependent mode. In conclusion, marked OS exists in
the 2K1C hypertensive rat model as described in the data,
which participates in cardiovascular remodeling and endo-
thelial dysfunction, at least in part. Chronic treatment with
XJEK prevents these pathological changes as well as the
positive drug-fosinopril. The protective effect is most likely
due to the ability of XJEK to attenuate OS and/or by im-
proving ED and increasing NO release in this 2K1C hyper-
tensive rat model.
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